ATE398136T1 - Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren - Google Patents

Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren

Info

Publication number
ATE398136T1
ATE398136T1 AT97909070T AT97909070T ATE398136T1 AT E398136 T1 ATE398136 T1 AT E398136T1 AT 97909070 T AT97909070 T AT 97909070T AT 97909070 T AT97909070 T AT 97909070T AT E398136 T1 ATE398136 T1 AT E398136T1
Authority
AT
Austria
Prior art keywords
therapeutic
cytokine
diagnostics
signal transduction
present
Prior art date
Application number
AT97909070T
Other languages
English (en)
Inventor
Douglas Hilton
Warren Alexander
Elizabeth Viney
Tracy Willson
Rachael Richardson
Robyn Starr
Sandra Nicholson
Donald Metcalf
Nicos Nicola
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO3384A external-priority patent/AUPO338496A0/en
Priority claimed from AUPO5117A external-priority patent/AUPO511797A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Application granted granted Critical
Publication of ATE398136T1 publication Critical patent/ATE398136T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97909070T 1996-11-01 1997-10-31 Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren ATE398136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO3384A AUPO338496A0 (en) 1996-11-01 1996-11-01 Therapeutic and diagnostic agents
AUPO5117A AUPO511797A0 (en) 1997-02-14 1997-02-14 Therapeutic and diagnostic agents-II

Publications (1)

Publication Number Publication Date
ATE398136T1 true ATE398136T1 (de) 2008-07-15

Family

ID=25645307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97909070T ATE398136T1 (de) 1996-11-01 1997-10-31 Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren

Country Status (13)

Country Link
US (1) US20080166730A1 (de)
EP (2) EP1975234A2 (de)
JP (2) JP2001502183A (de)
KR (2) KR20000053017A (de)
CN (2) CN1253565A (de)
AT (1) ATE398136T1 (de)
CA (1) CA2270171A1 (de)
DE (1) DE69738767D1 (de)
DK (1) DK0948522T3 (de)
ES (1) ES2308785T3 (de)
GB (1) GB2331753A (de)
NO (1) NO992116L (de)
WO (1) WO1998020023A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
JPH11103867A (ja) * 1997-05-07 1999-04-20 Smithkline Beecham Corp Ｅｐｏ一次応答遺伝子１、ｅｐｒｇ１
AU8484698A (en) * 1997-07-18 1999-02-10 Schering Corporation Suppressors of cytokine signaling socs16; related reagents
CA2276685A1 (en) * 1997-11-03 1999-05-14 Incyte Pharmaceuticals, Inc. Suppressor of cytokine signaling
WO1999040946A2 (en) * 1998-02-11 1999-08-19 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
EP0953636A3 (de) 1998-03-23 2000-03-29 Smithkline Beecham Plc Cytokin-Signal Regulator
EP1064368A1 (de) * 1998-03-23 2001-01-03 Smithkline Beecham Plc Suppressoren des cytokinsignals
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
WO1999061614A2 (en) * 1998-05-28 1999-12-02 Incyte Pharmaceuticals, Inc. Human socs proteins
SE9803398D0 (sv) * 1998-10-06 1998-10-06 Sahltech Ab "New use"
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
AU4651900A (en) * 1999-04-20 2000-11-02 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
DE60038977D1 (de) * 1999-11-16 2008-07-03 Inst Medical W & E Hall Tiermodell für hormonsignalstudien und verfahren zum verändern der signalübertragung
AU784277B2 (en) * 1999-11-16 2006-03-02 Walter And Eliza Hall Institute Of Medical Research, The An animal model for studying hormone signalling and method of modulating the signalling
AU2001251612A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2425194A1 (en) * 2000-10-09 2002-04-18 Andrew Nash Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal
GB2373502A (en) * 2000-11-08 2002-09-25 Smithkline Beecham Corp Suppressor of cytokine signalling 4 (SOCS4)
EP1341913A2 (de) * 2000-12-14 2003-09-10 PHARMACIA & UPJOHN COMPANY Socs (suppressor der cytokin signalierung)
AUPR556601A0 (en) * 2001-06-08 2001-07-12 Ludwig Institute For Cancer Research Therapeutic and diagnostic molecules - II
WO2003072778A1 (fr) * 2002-02-27 2003-09-04 Genox Research, Inc. Methode pour etudier une maladie allergique
WO2005086800A2 (en) * 2004-03-04 2005-09-22 Vanderbilt University Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
JP2005312364A (ja) * 2004-04-28 2005-11-10 Mitsuo Itakura 糖尿病治療剤スクリーニング方法
EP1849474B1 (de) * 2005-02-15 2016-09-07 Toagosei Co., Ltd. Antimikrobielles peptid und verwendung davon
EP2427210A4 (de) * 2009-05-08 2012-10-24 Inst Medical W & E Hall Modulation der bindung von induzierbarer stickoxidsynthase (inos) an spry-domain-haltige socs-box-peptide (ssb)
KR101124622B1 (ko) * 2009-10-26 2012-03-19 한국생명공학연구원 Ｓｏｃｓ２ 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법
EP4253412A3 (de) 2015-12-16 2023-11-22 The Walter and Eliza Hall Institute of Medical Research Hemmung von cytokininduziertem sh2-protein in nk-zellen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
CA2143491C (en) * 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
EP0832117A1 (de) * 1995-06-05 1998-04-01 The Trustees Of Dartmouth College Genexpression, stimuliert durch liganden
AU4723797A (en) * 1997-01-10 1998-08-03 Tadamitsu Kishimoto Novel stat function-regulatory protein
AU8484698A (en) * 1997-07-18 1999-02-10 Schering Corporation Suppressors of cytokine signaling socs16; related reagents

Also Published As

Publication number Publication date
JP2009060903A (ja) 2009-03-26
NO992116L (no) 1999-06-29
JP2001502183A (ja) 2001-02-20
EP0948522A1 (de) 1999-10-13
WO1998020023A1 (en) 1998-05-14
ES2308785T3 (es) 2008-12-01
GB9905020D0 (en) 1999-04-28
EP0948522B1 (de) 2008-06-11
DK0948522T3 (da) 2008-09-22
EP0948522A4 (de) 2001-09-19
KR100719080B1 (ko) 2007-05-16
EP1975234A2 (de) 2008-10-01
US20080166730A1 (en) 2008-07-10
KR20000053017A (ko) 2000-08-25
CA2270171A1 (en) 1998-05-14
DE69738767D1 (de) 2008-07-24
GB2331753A (en) 1999-06-02
NO992116D0 (no) 1999-04-30
CN101280305A (zh) 2008-10-08
CN1253565A (zh) 2000-05-17
KR20060053007A (ko) 2006-05-19

Similar Documents

Publication Publication Date Title
ATE398136T1 (de) Therapeutika und diagnostika, die die zelluläre ansprechbarkeit auf cytokine regulieren
ATE221054T1 (de) Substituierte oxazolyl-derivate zur behandlung von entzündungen
DE3586863D1 (de) Verstaerker mit eingangsfaehigkeit ueber den gesamten versorgungsspannungsbereich und geregelter transkonduktanz.
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
ID30373A (id) PARAHERKUAMIDA ANTIPARASIT (Pecahan P-962086)
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
ATE150299T1 (de) Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
ATE286125T1 (de) Regulation der genexpression von bcl-2
GEP20043349B (en) Methods of Controlling Cutworm Pests
MY107573A (en) 2,4- and 2, 5-substituted pyridine-n-oxides, processes for their preparation and their use.
ATE227561T1 (de) Verwendung von alpha-alkylglucosiden und deren estern als antimikrobielle emulgatoren
DE69522671T2 (de) Elektroaktiver Werkstoff, seine Herstellung und seine Verwendung zur Herstellung von kathodischen Elementen
DE69510729D1 (de) Suspensionskonzentrat von insektiziden und akariziden Arylpyrrolen
WO1987004923A3 (fr) Amides aromatiques absorbant les u.v.
ATE222896T1 (de) Substituierte thiazoline und ihre verwendung zur bekämpfung von tierischen schädlingen
ATE270469T1 (de) Begrenzungsschaltung für einen analogen verstärker
ATE224201T1 (de) Verwendungen von alpha-lactalbumin zusammensetzungen
DE69327693D1 (de) Interferon-Alpha/Beta bindendes Protein, seine Herstellung und seine enthaltende pharmazeutische Zusammensetzungen
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
DE58906618D1 (de) Strobilurinderivate, ihre Herstellung und Verwendung.
DE69409961T2 (de) Triarylethylenderivate zur therapeutischen verwendung
DE287063T1 (de) Schaltung zum automatischen regeln des verstaerkung-bandbreite-produktes von operationsverstaerkern.
ES8204252A1 (es) Una disposicion de etapa de salida en contrafase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties